ClinicalTrials.gg
Status unknownNCT05328921Updated Apr 14, 2022

Effects of Systemic Drugs on Intraocular Pressure

An observational study in Glaucoma, Angle-Closure, Glaucoma Suspect and Glaucoma Secondary to Drugs, Bilateral, sponsored by Benha University. Status unknown at 1 site in Egypt. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-04-14.

Sponsored by Benha University · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
200
Ages
35 Years to 70 Years
Sex
All
01

Study summary

To assess intraocular pressure changes among glaucoma patients on systemic antihypertensive and antihistaminic drugs.

Read the detailed description

Changes in intraocular pressure in glaucomatous patients with narrow angle may elicit attacks of angle closure glaucoma.

In this study we aim to assess changes in intraocular pressure (IOP) among glaucomatous patients on systemic antihypertensive and antihistaminic drugs.

02

Conditions studied

  • Glaucoma, Angle-Closure
  • Glaucoma Suspect
  • Glaucoma Secondary to Drugs, Bilateral
  • Hypertension

Keywords

  • Angle closure glaucoma
  • Hypertension
  • Antihistaminic
  • Antihypertensive
03

In context

Glaucoma, Angle-Closure

91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.

This study's planned enrollment of 200 is below the median of 225 across 32 observational studies indexed under Glaucoma, Angle-Closure.

Browse Glaucoma, Angle-Closure studies →

Lead sponsor

Benha University is the lead sponsor of 362 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Glaucoma patients regularly visit glaucoma clinic at Banha university, EGYPT

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with narrow angle glaucoma on systemic antihypertensive and/or antihistaminic drugs.

Exclusion criteria

Exclusion Criteria:

  • open angle glaucoma patients confirmed by gonioscopy examination.
  • Cases with dense corneal opacity or iris trauma that may affects gonioscopy examination.
  • cases with secondary glaucoma.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Antihypertensive drugs group

    Changes in IOP among patients on antihypertensive drugs

    Drug: Antihypertensive Agents

  • Antihistaminic drugs group

    Changes in IOP among patients on antihistaminic drugs

    Drug: Antihistaminics

  • Antihypertensive and antihistaminic drugs group

    Changes in IOP among patients on both antihypertensive and antihistaminic drugs

    Drug: Antihypertensive Agents · Drug: Antihistaminics

Interventions

  • DrugAntihypertensive Agents

    Patients with narrow angle glaucoma and on systemic antihypertensive drugs.

  • DrugAntihistaminics

    Patients with narrow angle glaucoma and on systemic antihistaminic drugs.

06

What researchers measure

Primary outcomes

  1. Changes in intraocular pressure (IOP) measured by applanation tonometry

    Changes in IOP measured by millimeter mercury (mmHg)

    Time frame: Immediately after visual acuity assessment for each eye after topical anesthetic eye drops and again on one and three months visit

Secondary outcomes

  1. Changes in pupil diameter

    Size of pupil measured in millimeters (mm) 7sing autorefractometer

    Time frame: Immediately after slit lamp examination and again on one and three months visit

07

Study locations

1 of 1 sites recruiting
  • Ahmed Abdelshafy
    Banhā, QA 13511, Egypt
    Recruiting
    • Ahmed Abdelshafy, MD · Contactahmad4lg@gmail.com · 01222328766
    • Marwa Abdelshafy, MD · Contactahmad4lg@gmail.com · 01222328766
    • Ahmed Abdelshafy, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Sep 2022, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 14, 2022
StartActual
Apr 7, 2022
Primary completionEst.
Sep 15, 2022
CompletionEst.
Sep 30, 2022
Last update
Apr 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05328921
Lead sponsor
Benha University
Responsible party
Ahmed Abdelshafy (Lecturer of Ophthalmology, Benha University) — Principal investigator
First posted
Apr 14, 2022
Start date
Apr 7, 2022
Primary completion
Sep 15, 2022 (estimated)
Completion
Sep 30, 2022 (estimated)
Last update
Apr 14, 2022

Study contacts

Ahmed Abdelshafy, MD
Contact
ahmad4lg@gmail.com
01222328766
Marwa Abdelshafy, MD
Contact
ahmad4lg@gmail.com
01222328766

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion